I am new to this board, but very impressed with th
Post# of 153800
(Total Views: 1768)
Posted On: 07/07/2020 12:48:01 PM
Re: HHIGambler #41350
I am new to this board, but very impressed with the knowledge base and the true desire to help all the investors.
By way of introduction, I am an MD but spent several years doing bench top research in a prominent virology lab. In fact, BP was a classmate of mine in our undergrad path to a degree in cell and molecular biology,
That was a nice post,
My thoughts:
1. COVID, AND THE EMERGENCE OF SARS COV-2, WHICH ATTACKS MULIPLE ORGAN SYSTEMS, IS UNHEARD IN THE WORLD OF VIROLOGY
2. THE WORLD EPIDEMIC HAS BROUGHT TREMENDOUS AND UNPRECEDENTED DOLLARS, AND COOPERATION IN MEDICINE AND INDUSTRY.
3, THE ELUCIDATION OF THE RANTES PATHWAY AND THE DISCOVERY THE DELTA 32 MUTATION (INABILITY) TO EXPRESS THE CCR 5 RECEPTOR WAS A MAJOR CONTRIBUTION IN THIS FIELD.
4. ANTI-VIRALS AND VACCINES AND TARGETING IL6 WILL NOT BE THE ANSWER. A INFECTIOUS DISEASE EXPERT AND COLLEAGUE HAS HAD CLINICAL EXPERIENCE WITH THESE DRUGS IN A COVID UNIT HE WAS RUNNING WITH DISMAL RESULTS.
5. RETRACTIONS FROM MAJOR JOURNALS IS A REFLECTION OF POOR EDITORIAL REVIEWS AND NOT RESTRICTION TO LEVEL ONE STUDIES, IS WAS ON THE EDITORIAL OF A MAJOR JOURNAL AND IF IT WAS NOT LEVEL 1, IT WENT INTO THE GARBAGE.
6.CYTODYN'S ARE VERY WELL DESIGNED AND SO FAR MEETS THE PARAMETERS OF A LEVEL 1 STUDY AND WILL MOST CERTAINLY BE PUBLISHED EVEN BEFORE FDA APPROVAL, WHICH WILL RESULT IN INCREASED PRESSURE FROM DOCTORS AND SCIENTISTS ON THE FDA.
7. IF THE BLA FOR HIV IS APPROVED FIRST, PHYSICIANS CAN USE IT OFF LABEL FOR COVID EVEN IF THEY ARE NOT IN A CLINICAL TRIAL.
THIS ALONE WILL STIMULATE SALES AND FURTHER PUBLICATIONS.
8. IF RANTES IS TRULY THE MASTER PROTEIN OF THE INFLAMMATORY RESPONSE, IT WILL HAVE MY APPLICATIONS.IE EVERYTHING FROM GI DISEASES, RHEUMATOLOGY , CARDIOGY, AND DERMATOLOGY. VIRTUALLY AN UNLIMITED MARKET. 2 YEARS FROM NOW THE PROFIT FROM COVID WILL BE A FRACTION OF FUTURE PROFITS.
I10. IN TERMS OF PRODUCTION CAPACITY, I WOULDN'T BE SURPRISED IF THE NEXT PARTNERSHIP WILL BE WITH SANOFI (LARGEST PRODUCER OF VACCINES IN THE WORLD).
By way of introduction, I am an MD but spent several years doing bench top research in a prominent virology lab. In fact, BP was a classmate of mine in our undergrad path to a degree in cell and molecular biology,
That was a nice post,
My thoughts:
1. COVID, AND THE EMERGENCE OF SARS COV-2, WHICH ATTACKS MULIPLE ORGAN SYSTEMS, IS UNHEARD IN THE WORLD OF VIROLOGY
2. THE WORLD EPIDEMIC HAS BROUGHT TREMENDOUS AND UNPRECEDENTED DOLLARS, AND COOPERATION IN MEDICINE AND INDUSTRY.
3, THE ELUCIDATION OF THE RANTES PATHWAY AND THE DISCOVERY THE DELTA 32 MUTATION (INABILITY) TO EXPRESS THE CCR 5 RECEPTOR WAS A MAJOR CONTRIBUTION IN THIS FIELD.
4. ANTI-VIRALS AND VACCINES AND TARGETING IL6 WILL NOT BE THE ANSWER. A INFECTIOUS DISEASE EXPERT AND COLLEAGUE HAS HAD CLINICAL EXPERIENCE WITH THESE DRUGS IN A COVID UNIT HE WAS RUNNING WITH DISMAL RESULTS.
5. RETRACTIONS FROM MAJOR JOURNALS IS A REFLECTION OF POOR EDITORIAL REVIEWS AND NOT RESTRICTION TO LEVEL ONE STUDIES, IS WAS ON THE EDITORIAL OF A MAJOR JOURNAL AND IF IT WAS NOT LEVEL 1, IT WENT INTO THE GARBAGE.
6.CYTODYN'S ARE VERY WELL DESIGNED AND SO FAR MEETS THE PARAMETERS OF A LEVEL 1 STUDY AND WILL MOST CERTAINLY BE PUBLISHED EVEN BEFORE FDA APPROVAL, WHICH WILL RESULT IN INCREASED PRESSURE FROM DOCTORS AND SCIENTISTS ON THE FDA.
7. IF THE BLA FOR HIV IS APPROVED FIRST, PHYSICIANS CAN USE IT OFF LABEL FOR COVID EVEN IF THEY ARE NOT IN A CLINICAL TRIAL.
THIS ALONE WILL STIMULATE SALES AND FURTHER PUBLICATIONS.
8. IF RANTES IS TRULY THE MASTER PROTEIN OF THE INFLAMMATORY RESPONSE, IT WILL HAVE MY APPLICATIONS.IE EVERYTHING FROM GI DISEASES, RHEUMATOLOGY , CARDIOGY, AND DERMATOLOGY. VIRTUALLY AN UNLIMITED MARKET. 2 YEARS FROM NOW THE PROFIT FROM COVID WILL BE A FRACTION OF FUTURE PROFITS.
I10. IN TERMS OF PRODUCTION CAPACITY, I WOULDN'T BE SURPRISED IF THE NEXT PARTNERSHIP WILL BE WITH SANOFI (LARGEST PRODUCER OF VACCINES IN THE WORLD).
(24)
(0)